KMD Bioscience has established a comprehensive technical service system centered on its protein platform, antibody platform, and phage display platform. Its protein platform features a complete system for in vitro recombinant protein expression, fermentation, purification, and quality control, and its team of scientists has many years of experience in the development of human protein-based therapeutics; This platform supports four major protein expression systems: prokaryotic (E. coli), yeast (Pichia pastoris, Saccharomyces cerevisiae), insect (SF9 cells), and mammalian (CHO, HEK293F, etc.), while also providing comprehensive services such as industrial-scale protein fermentation and lyophilization, natural protein purification, protein sequencing, and labeling. The antibody platform covers custom monoclonal antibody production (a mouse monoclonal antibody platform based on hybridoma technology, capable of generating high-affinity, high-specificity monoclonal antibodies within 2–3 months), polyclonal antibody production (from multiple species, including rabbits, sheep, and camels), and custom recombinant monoclonal antibody services; It also provides upstream and downstream support services such as antibody purification, antibody sequencing (de novo full-length sequence analysis and N-terminal sequencing), and antibody engineering (including chimeric antibody production, antibody affinity maturation, and antibody humanization). The phage display platform can construct diverse natural libraries (mouse, rabbit, human, etc.), immunological libraries (VHH, scFv, Fab libraries), synthetic libraries (peptide libraries), and semi-synthetic libraries, and provides professional library screening and selection services. We have extensive experience in antibody discovery for challenging targets such as GPCRs and ion channels. In addition, KMD Bioscience has established platforms for peptide synthesis, single B-cell screening, stable cell line construction and strain development, as well as viral vector and cell technology. These platforms extensively support the R&D of recombinant proteins, antibodies, target proteins for antibody drugs, industrial enzymes, diagnostic raw materials, and other related reagents.